1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

AstraZeneca: Don’t Write Off Fasenra In COPD Just Yet

 
• By Andrew McConaghie

AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.

Eosinophil
Eosinophils in action: AstraZeneca is trying again in COPD • Source: Shutterstock

AstraZeneca PLC and GlaxoSmithKline PLC both hit a brick wall last year when trying to show their eosinophil-targeting drugs could treat COPD as well as asthma, but AstraZeneca isn’t giving up just yet.

Its Fasenra (benralizumab) is in pursuit of GSK’s Nucala (mepolizumab) in the eosinophilic asthma market, and its revenues look to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

More from Therapy Areas

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.